Weight Loss & MetabolicHigh evidence

Retatrutide

Peptide therapy: benefits, side effects, cost and protocols

Retatrutide (LY-3437943) is an experimental triple glucagon hormone receptor agonist (GIP/GLP-1/glucagon) developed by Eli Lilly for obesity treatment. It represents a novel approach targeting three metabolic pathways simultaneously for enhanced weight loss efficacy.

ByChris Riley(CFA)|Updated October 10, 2026

Sources: FDA / PubMed / ClinicalTrials.gov View

Spec sheet

FDA status: Research Only Not currently approved for human use in the US. Available as a research compound. Not eligible for compounding.
Evidence: Strong Evidence

Find a provider

Who it's for

Who Retatrutide is usually considered for

Significant weight loss potential
Triple receptor activation
Metabolic enhancement
Appetite control

Mechanism

How Retatrutide works

Triple agonist targeting GLP-1 (appetite/insulin), GIP (metabolic efficiency), and glucagon (fat burning) receptors for synergistic metabolic effects.

Evidence

Key studies

198 papers on PubMed / 121 human trials

01
Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials
02
Giblin K, Kaplan LM, Somers VK et al
Diabetes Obes Metab / Diabetes Obes Metab / Phase 3
03
Retatrutide reduces body weight, apnea-hypopnea index, and knee osteoarthritis pain
04
Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial
05
Jastreboff AM, Kaplan LM, Frías JP et al
N Engl J Med / Phase 2
Retatrutide produced dose-dependent weight loss up to 24.2% at 48 weeks versus 2.1% for placebo.
06
Retatrutide produced dose-dependent weight loss up to 24.2% at 48 weeks versus 2.1% for placebo
07
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
08
Rosenstock J, Frias J, Jastreboff AM et al
Lancet / Phase 2
Retatrutide improved HbA1c by up to 2.02% and reduced body weight by up to 16.94% in type 2 diabetes.
09
Retatrutide improved HbA1c by up to 2.02% and reduced body weight by up to 16.94% in type 2 diabetes
10
Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial

FAQ

Retatrutide questions

What is RETATRUTIDE?

Retatrutide is a triple agonist peptide representing the cutting edge of weight loss research. It targets GLP-1, GIP, and glucagon receptors simultaneously, showing remarkable results in clinical trials for weight reduction.

How does RETATRUTIDE work?

Triple agonist targeting GLP-1 (appetite/insulin), GIP (metabolic efficiency), and glucagon (fat burning) receptors for synergistic metabolic effects.

Is RETATRUTIDE legal to buy?

RETATRUTIDE is sold as a research chemical for laboratory use only. It is not approved for human use by the FDA. Regulations vary by jurisdiction.

Where can I buy RETATRUTIDE?

RETATRUTIDE is available as a research compound from verified online vendors. Always verify third-party testing before purchasing.

What category does RETATRUTIDE belong to?

RETATRUTIDE is primarily classified as a weight loss & metabolic peptide. Peptides researched for their effects on weight management, fat metabolism, appetite regulation, and metabolic enhancement. This category includes GLP-1 agonists, dual/triple agonists, and other metabolic peptides.

What are the research benefits of RETATRUTIDE?

RETATRUTIDE has been studied for: Significant weight loss potential, Triple receptor activation, Metabolic enhancement, Appetite control. Triple agonist; highest demand peptide in current research.

News

Retatrutide in the news

News aggregated via Google News. Inclusion does not imply endorsement.

Considering Retatrutide?

The 2-minute quiz matches you with licensed providers who offer it. A clinician decides if it fits.

Take the quiz